On October 20, 2026, the AANS/CNS Washington Committee hosted a webinar exploring the Food and Drug Administration’s (FDA) Medical Device User Fee Amendments (MDUFA) and the upcoming reauthorization process. The webinar provided an overview of how MDUFA supports the review and evaluation of new medical technologies, while establishing processes that help ensure timely patient access to safe and effective devices.

Moderated by Joshua M. Rosenow, MD, Chair of the AANS/CNS Drugs and Devices Subcommittee, the discussion featured expert perspectives from Kathryn Capanna, MBA, Associate Director of the FDA Office of Strategic Partnerships and Technology Innovation; David McMullen, MD, Head of Medical Affairs at Neuralink; and Cory N. Criss, MD, Chief Operating Officer of the Midwest Pediatric Device Consortium. Speakers examined the role of MDUFA in shaping the medical device ecosystem, discussed the regulatory challenges associated with emerging neurotechnologies, and highlighted pediatric and rare disease device development. Panelists also explored opportunities for stakeholder engagement during reauthorization and discussed priorities for ensuring that future MDUFA agreements support the development, review, and availability of technologies that improve care for patients with neurological conditions.